AbelZeta reports 91.7% disease control rate in Phase I liver cancer trial of C-CAR031
AZN•AbelZeta reported a 91.7% disease control rate in a Phase I trial of C-CAR031, now AZD7003, in advanced liver cancer. Results from 36 heavily pretreated patients showed tumor shrinkage and a manageable safety profile, with serious inflammatory reactions and lung disease at the highest dose.
1. Trial results
Updated Phase I results for C-CAR031, now AZD7003, in advanced liver cancer showed tumor shrinkage and an encouraging survival signal among 36 heavily pretreated patients. The treatment had a manageable safety profile; serious inflammatory reactions and lung disease occurred at the highest dose, though no dose-limiting toxicities were observed.
2. Development rights
AstraZeneca holds sole worldwide development, manufacturing and commercialization rights after acquiring the remaining China rights in January 2026. AbelZeta remains eligible for milestone payments and royalties under existing agreements.
